



Flublok® Influenza Vaccine is a great alternative for FluMist for adults 18 and older

For Immediate Release

June 30, 2016

Contact:

Courtney Reis
Communications Associate
Phone: (203) 686-0800 ext. 301

Meriden, CT — On Wednesday, the CDC's Advisory Committee on Immunization Practices (ACIP) recommended *against* the use of live attenuated influenza vaccine (LAIV), also known as the "nasal spray" flu vaccine and marketed as FluMist®, for the 2016/17 flu season. The decision was based on data that showed poor effectiveness of LAIV from 2013 through 2016. Without FluMist, 14 million less doses of flu vaccine will be available this fall.

FluMist is approved for ages 2-49 and its absence will impact both pediatric and adult flu vaccine supply. Providers should anticipate that remaining supplies of recommended flu vaccines will be depleted quickly. It is advisable to plan ahead and pre-book replacement vaccines now.

Flublok influenza vaccine, a pure protein flu vaccine with high efficacy, low side effects and no harmful additives, is CDC recommended and a great alternative for the adult population.

Why Flublok?

- Flublok is a safe and effective flu vaccine for the entire adult population. It is a pure protein vaccine – only flu vaccine made without influenza virus, antibiotics, formaldehyde, eggs, thimerosal (that contains mercury), latex or gelatin
- Sought after by millennials, pregnant women, immune-compromised patients, holistics, and many others
- Superior efficacy in a 2014/15 post-marketing study*
- 3X more active ingredients than traditional flu vaccines*
- Approved for adults 18 years and older
- Fully covered by most insurance companies, including Medicare/Medicaid
- **Now with a 9 month shelf life**

To pre-order Flublok for 2016/17, contact Protein Sciences or one of these distributors:

- Protein Sciences Corporation: 203-686-0800
- FFF Enterprises: 800-843-7477 www.myfluvaccine.com
- Cardinal Health: 866-677-4844 <http://www.cardinal.com/us/en/SPD/Ordering>
- McKesson: 877-MCK-4FLU mms.mckesson.com

- Henry Schein: 1-800-772-4346 www.henryschein.com

For more information about Flublok, please visit www.flublok.com.

About Protein Sciences

Protein Sciences specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals.

Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, was approved by FDA in January 2013. Flublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus or antibiotics in manufacturing. Flublok is highly purified and does not contain any preservatives (e.g., thimerosal, a mercury derivative), egg proteins, gelatin or latex. In addition, Flublok contains three times more antigen than traditional flu vaccines (3x45mcg hemagglutinin protein versus 3x15mcg hemagglutinin protein)*. Flublok is a perfect copy of the virus coat and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see [Skowronski et al. \(2014\) PLOS ONE 9\(3\), e92153](#)).

Flublok Safety Information

Flublok is approved for people 18 and older to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Headache, fatigue or muscle ache may occur. Tell the doctor if you have ever experienced Guillain-Barré syndrome (severe muscle weakness) or have had a severe allergic reaction to any component of Flublok vaccine. Vaccination with Flublok may not protect all individuals. Clinical effectiveness in adults 50 and older is based on the immune response elicited by Flublok and not on demonstration of decreased influenza disease. Please see the complete Package Insert available at www.flublok.com or call 203-686-0800 for more information.

*Flublok demonstrated a higher antibody response to the A strains during 2 clinical trials in adults ≥50 years old. The B strain antibody response was comparable to traditional trivalent vaccines.

###